One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study
Figure 1
Number of ranibizumab injections received during year 1 in the retrospectively and prospectively recruited subpopulations (on-treatment population, ).